Advertisement

Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from the Benelux countries Belgium, Luxembourg and The Netherlands or involving organisations from these countries.

Total search results: 1815 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Lava Therapeutics–Bellevue: investment, 202009 financing round Series C totalling $83m incl new + co-investor BB Pureos Bioventures 2020-09-17
Lava Therapeutics–Gilde Investment: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Gilde Healthcare 2020-09-17
Lava Therapeutics–Merck (US): investment, 202009 financing round Series C totalling $83m incl existing + co-investor MRL Ventures Fund LLC 2020-09-17
Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures 2020-09-17
Lava Therapeutics–Redmile Group: investment, 202009 financing round Series C totalling $83m incl new + co-investor Redmile Biopharma Investments 2020-09-17
Lava Therapeutics–Sanofi: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Sanofi Ventures 2020-09-17
Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures 2020-09-17
Lava Therapeutics–Versant Ventures: investment, 202009 financing round Series C totalling $83m incl existing + co-investor Versant 2020-09-17
Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital 2020-09-17
Neogene Therapeutics–EcoR1 Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor EcorR1 Capital 2020-09-14
Neogene Therapeutics–Jeito Capital: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Jeito Capital 2020-09-14
Neogene Therapeutics–Polaris Partners: investment, 202009 financing round Series A totalling $110m incl new + co-investor Polaris Partners 2020-09-14
Neogene Therapeutics–Pontifax: investment, 202009 financing round Series A totalling $110m incl new + co-investor Pontifax 2020-09-14
Neogene Therapeutics–SEVERAL: investment, 202009 financing round Series A $110m co-led by EcorR1 Capital + Jeito Capital + Syncona 2020-09-14
Neogene Therapeutics–Syncona: investment, 202009 financing round Series A totalling $110m incl new + co-lead investor Syncona 2020-09-14
Neogene Therapeutics–Texas Pacific Group: investment, 202009 financing round Series A totalling $110m incl existing + co-investor TPG 2020-09-14
Neogene Therapeutics–Two River: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Two River 2020-09-14
Neogene Therapeutics–Vida Ventures: investment, 202009 financing round Series A totalling $110m incl existing + co-investor Vida Ventures 2020-09-14
Oncomfort–SEVERAL: investment, 202009 financing round Series A €10m co-led by Debiopharm + Crédit Mutuel Innovation 2020-09-09
United States (govt)–Intravacc: EV D68 vaccine, 202009– co-development contract up to $9.4m for prophylactic enterovirus D68 vaccine with NIAID 2020-09-08
Amarna Therapeutics–LifeSpring: public relations, 202009 service existent by LifeSpring Communications 2020-09-03
Biocartis–LifeArc: molecular diagnostics, 202009– collab expansion €na developm of MDx tests for infectious + immune diseases for Idylla platform 2020-09-01
Semalytix–SEVERAL: investment, 202008 financing round Series A €4.3m co-led by btov + Fly Ventures 2020-08-31
Intact Vascular–Philips: investment, 202008– acquisition $275m upfront + $85m at closing of transaction 2020-08-27
NewAmsterdam Pharma–Forbion: investment, 202008 seed financing round totalling €20m from Forbion + founders 2020-08-25
NewAmsterdam Pharma–McDougall Communications: public relations, 202008 service existent by McDougall 2020-08-25
NewAmsterdam Pharma–SEVERAL: investment, 202008 seed financing round €20m from Forbion + founders 2020-08-25
Galapagos–Scipher Medicine: AI-based drug discovery, 202008– collab IBD drug target valuation with excl option rights for developm for Galapagos 2020-08-12
Atriva Therapeutics–Meneldor: credit, 202008– convertible loan financing round totalling €8.6m incl existing + co-lead investor Meneldor BV 2020-08-11
Atriva Therapeutics–SEVERAL: credit, 202008– convertible loan financing round €8.6m led by existing investors Meneldor + HTGF 2020-08-11
CureVac–SEVERAL: investment, 202008 IPO $245.3m with 13.3m+2m common shares at $16/share at Nasdaq Global Market 2020-08-10
Dyne Therapeutics–Forbion: investment, 202008 financing round totalling $115m incl existing + co-investor Forbion 2020-08-10
Dyne Therapeutics–SEVERAL: investment, 202008 financing round $115m co-led by new investors Vida Ventures + Surveyor Capital 2020-08-10
DNA Script–SEVERAL: investment, 202007 financing round Series B extension $50m led by Casdin Capital 2020-07-29
Vico Therapeutics–LifeSpring: public relations, 202007 service existent by LifeSpring Communications 2020-07-29
ExeVir Bio–Belgium (govt): investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor SFPI-FPIM 2020-07-28
ExeVir Bio–Fund+: investment, 202007 financing round Series A 1st closing totalling €23m incl lead investor Fund+ 2020-07-28
ExeVir Bio–Optimum Strategic Communications: public relations, 202007 service existent by Optimum 2020-07-28
ExeVir Bio–OTHER: investment, 202007 financing round Series A 1st closing totalling €23m incl several Belgian family offices 2020-07-28
ExeVir Bio–SEVERAL: investment, 202007 financing round Series A 1st closing of €23m led by Fund+ 2020-07-28
ExeVir Bio–UCB: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor UCB Ventures 2020-07-28
ExeVir Bio–V-Bio Ventures: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor V-Bio Ventures 2020-07-28
ExeVir Bio–VIB: investment, 202007 financing round Series A 1st closing totalling €23m incl co-investor VIB 2020-07-28
Sanofi–Kiadis: NK cell therapy, 202007– license ww excl for K-NK004 program + two other programs €17.5m upfront + €857.5m milestones + royalties 2020-07-08
VarmX–Instinctif Partners: public relations, 202007 service existent by Instinctif 2020-07-08
VarmX–SEVERAL: investment, 202007 financing round Series B €32m co-led by Ysios Capital + INKEF Capital 2020-07-08
CVRx–Gilde Investment: investment, 202007 equity investment totalling $50m incl existing + co-investor Gilde Healthcare 2020-07-07
CVRx–SEVERAL: investment, 202007 raises $50m equity investment to close latest financing round co-led by SHLP + Vensana Capital 2020-07-07
Citryll–BioGeneration Ventures: investment, 202007 financing round Series A totalling €18.5m incl new + co-lead investor BioGeneration Ventures 2020-07-02
Citryll–BPCE: investment, 202007 financing round Series A totalling €18.5m incl new + lead investor Seventure incl its Health for Capital II fund 2020-07-02
Citryll–Netherlands (govt): credit, 202007 Innovation Credit from RVO 2020-07-02
Citryll–SEVERAL: investment, 202007 financing round Series A €18.5m led by Seventure + co-led by BioGeneration Ventures 2020-07-02
Cergentis–Novalis Biotech Incubation: investment, 202006 investment by Novalis Biotech Incubation fund 2020-06-29
CSL–Uniqure: gene therapy, 202006– license excl ww $450m upfront + $1.6b milestones + royalties for hemophilia B gene therapy AMT-061 2020-06-24
Scenic Biotech–Netherlands (govt): credit, 202006– Innovation Credit €3.1m from RVO to advance QPCTL inhibitors 2020-06-23
ArcherDx–Invitae: investment, 202006– acquisition merger up to $1.4b with $325m cash + 30m shares + up to addit 27m shares milestone-dependent 2020-06-22
BlueBee–Illumina: investment, 202006 acquisition €na of BlueBee by Illumina 2020-06-17
China Grand Pharma–eTheRNA: mRNA technology, 202006– collab outline terms of potential strategic partnership R+D + production + sales in Greater China 2020-06-16
eTheRNA–BNP Paribas: investment, 202006 financing round Series B totalling €34m incl new investor BNP Paribas Fortis Equity 2020-06-16
eTheRNA–Boehringer: investment, 202006 financing round Series B totalling €34m incl existing investor BIVF 2020-06-16
eTheRNA–China Grand Pharma: investment, 202006 financing round Series B totalling €34m incl new investor Grand Decade 2020-06-16
eTheRNA–Flanders (govt): investment, 202006 financing round Series B totalling €34m incl existing investor PMV 2020-06-16
eTheRNA–Fund+: investment, 202006 financing round Series B totalling €34m incl existing investor Fund+ 2020-06-16
eTheRNA–Life Sciences Partners: investment, 202006 financing round Series B totalling €34m incl existing investor LSP 2020-06-16
eTheRNA–Novalis LifeSciences: investment, 202006 financing round Series B totalling €34m incl new investor Novalis LifeSciences LLC 2020-06-16
eTheRNA–Omega Funds: investment, 202006 financing round Series B totalling €34m incl existing investor Omega Funds 2020-06-16
eTheRNA–SEVERAL: investment, 202006 financing round Series B €34m from all existing + new investors 2020-06-16
eTheRNA–Yijing Capital: investment, 202006 financing round Series B totalling €34m incl new investor Yijing Capital 2020-06-16
Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ 2020-06-16
Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m 2020-06-16
Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital 2020-06-16
JnJ–Bavarian Nordic: vaccine, 202006– supply $13.9m manufacturing + delivery of MVA-BN Filo Ebola vaccine to Janssen Vaccines & Prevention BV 2020-06-12
Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Belfius Insurance 2020-06-10
Bioqube Ventures–Belgium (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor FPIM 2020-06-10
Bioqube Ventures–EU (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor EIF 2020-06-10
Bioqube Ventures–Flanders (govt): investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor PMV 2020-06-10
Bioqube Ventures–Genmab: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor Genmab 2020-06-10
Bioqube Ventures–JnJ: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl strategic investor JnJ Innovation 2020-06-10
Bioqube Ventures–Molenwater Groep: investment, 202006 first closing totalling €60m of Bioqube Factory Fund I incl investor Molenwater Groep 2020-06-10
Bioqube Ventures–SEVERAL: investment, 202006 first closing €60m of Bioqube Factory Fund I investors incl EIF + PMV + FPIM + Genmab + JJDC et al 2020-06-10
Hyloris Pharmaceuticals–SEVERAL: investment, 202006 IPO $65.2m at $12/share at Euronext Brussels 2020-06-03
Prilenia–Forbion: investment, 202006 financing round Series A totalling $62.5m incl new + lead investor Forbion 2020-06-03
Prilenia–Genworks 2: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Genworks 2 2020-06-03
Prilenia–Instinctif Partners: public relations, 202006 service existent by Instinctif 2020-06-03
Prilenia–Morningside: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Morningside Venture Investments 2020-06-03
Prilenia–Sectoral Asset Management: investment, 202006 financing round Series A totalling $62.5m incl new + co-investor Sectoral Asset Management 2020-06-03
Prilenia–SEVERAL: investment, 202006 financing round Series A $62.5m led by new investor Forbion 2020-06-03
Prilenia–Talisman Capital Partners: investment, 202006 financing round Series A totalling $62.5m incl existing + co-investor Talisman Capital Partners 2020-06-03
Kumovis–Ffilipa Venture Capital: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor Ffilipa Venture Capital 2020-05-27
Kumovis–High-Tech Gründerfonds: investment, 202005 financing round Series A totalling €3.6m incl existing + co-investor HTGF 2020-05-27
Kumovis–SEVERAL: investment, 202005 financing round Series A €3.6m led by Renolit + Solvay Ventures 2020-05-27
Kumovis–Solvay: investment, 202005 financing round Series A totalling €3.6m incl new + co-lead investor Solvay Ventures 2020-05-27
Argenx–SEVERAL: investment, 202005 global offering $862.5 via ADS offering in US + private placement in Europe 2020-05-26
Enzymicals–Syngulon: enzyme production technology, 202005– license non-excl to antibiotic-free selection technology of Syngulon 2020-05-16
OTHER–Enzymicals: enzymes, 202005 service production + supply of diagnostic enzymes using antibiotic-free production for undisclosed world leader 2020-05-16
JnJ–Lava Therapeutics: bispecific antibodies, 202005– collab €na research + license agreem for bispecfic gamma-delta T-cell engagers Janssen Biotech 2020-05-15
Polyganics–EU (govt): grant, 202005 EFRO grant €1.2m for clinical development of Liver + Pancreas Sealant Patch 2020-05-13
Polyganics–Instinctif Partners: public relations, 202005 service existent by Instinctif 2020-05-13
Hyloris Pharmaceuticals–Consilium: public relations, 202004 service existent by CSC 2020-04-30
Hyloris Pharmaceuticals–SEVERAL: investment, 202004 financing round €15m incl Scorpiaux + Noshaq + Staffelberg Investments + Nomainvest 2020-04-30
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  next pagenext page



Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [iito] Made Without Love 650x80px

» top